How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

AT

NASDAQ:ATHA
Get a brief AI stock analysisSaves ~ 15 minutes of your time

AT

Athira Pharma IncNASDAQ ATHA Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is ATHA undervalued compared to its fair value?

The fair value of ATHA stock is hidden USD. Relative to the market price of 3.11 USD Athira Pharma Inc is hidden.

Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. The company is headquartered in Bothell, Washington and currently employs 34 full-time employees. T...[More about valuation]

Athira Pharma Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

0.123 $B

Price:

3.11 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.716

FINANCIALS

Athira Pharma financial for reporting period

Income Statement


Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.031 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.027 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

Balance Sheet

0.16 B
0.13 B

Financial Position Analysis

Assets

0.16 B
Current Assets
0.15 B
Total non-current assets
0.0055 B

Total current liabilities
0.029 B
Total non-current liabilities
0.0012 B

Cash Flow Statement

-0.026 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.026 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Athira Pharma fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is ATHA attractive for investment based on fundamental analysis?

ATHA stock rating is hidden. Athira Pharma is a hidden by Eyestock methodology.

Get ATHA Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

Debt / Equity ratio:

ROE:

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

ATHA analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for ATHA to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Athira Pharma Inc competitors

LL

LLY

Eli Lilly and Co

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs ...

Discover

NO

NOVO B.CO

Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged i...

Discover

JN

JNJ

Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. The company is headquartered in Ne...

Discover

Athira Pharma Inc dividends

ATHA dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About ATHA stock

About the company Athira Pharma Inc

Market cap $B

0.123

Dividend yield

Shares outstanding

37.8293 B

Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. The company is headquartered in Bothell, Washington and currently employs 34 full-time employees. The company went IPO on 2020-09-18. The firm is focused on developing small molecules to restore neuronal health and stop neurodegeneration. The firm's lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, blood brain barrier (BBB)-penetrating, small molecule HGF/MET positive modulator. The primary target indication is Alzheimers disease. The ATH-1017, is a subcutaneous administered, BBB-penetrating, small molecule hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) activator for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer's disease (AD). The company also has preclinical candidates for non-AD indications, including ATH-1018, which is being developed to address peripheral indications, and ATH-1019/ATH-1020 compounds, which are being advanced to address neuropsychiatric indications. ATH technology is designed to promote HGF/MET activity for a variety of clinical applications.

ATHA profile

  • Ticker

    ATHA

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    18 September 2020

  • Sector

    Healthсare

  • Industry

    Pharmaceuticals

  • Employees

    34

  • City

    Bothell

  • Address

    18706 North Creek Parkway, Suite 104, Box 352141

  • Cusip

    04746L104